Camille Verry

Short Biography

Dr Verry is senior Radiation Oncologist (MD, PhD) at the University Hospital in Grenoble (France) since 2013, member of STROBE Inserm UA7 team, and associate researcher at Harvard Medical School, Boston (USA) December 2020 - August 2021 (Fulbright award). Dr Verry is coordinator of 2 clinical trials and principal investigator of 7 clinical trials concerning radiation therapy. He is expert in prostate cancer, brachytherapy, nanoparticles, radiosensitizer, European synchrotron, and brain metastasis. His research is focused on improving the efficacy of radiation therapy for incurable tumors using synchrotron radiation and nanoparticles. His PhD results has led to a first-in-man clinical trial with the injection of a gadolinium nanoparticle (AGuIX) as a radiosensitizing agent. He first demonstrated a radiosensitizing effect in a brain tumor animal model. Then he coordinated the phase 1 study concerning patients with multiple brain metastases treated by radiotherapy and AGuIX. The first encouraging results are currently being published (Theranostics and Sciences advances) and pave the way for NanoRad2 (NCT03818386) multicenter randomized trial currently recruiting. He is also co-investigator of another first in man study concerning brain metastases treated by synchrotron stereotactic radiation at ESRF (NCT 01640509). Dr Verry is co-author of 24 articles and 3 book chapters.

1. Verry C, Dufort S, Lemasson B, Grand S, Pietras J, I Troprès I, Crémillieux Y, Lux F, Mériaux S, Larrat B, Balosso J, Le Duc G, Barbier E, Olivier Tillement O. “Targeting brain metastases with theranostic nanoparticles, a first-in-human trial from an MRI perspective” Sciences Advances. 2020 (in press).
2. Bort G, Lux F, Dufort S, Crémillieux Y, Verry C, Tillement O. EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles. Theranostics. 2020; 10(3):1319-1331.
3. Verry C, Sancey L, Dufort S, Le Duc G, Mendoza C, Lux F, Grand S, Arnaud J, Quesada JL, Villa J, Tillement O, Balosso J. Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol. BMJ Open. 2019; 9(2): e023591.
4. Verry C, Dufort S, Barbier EL, Montigon O, Peoc'h M, Chartier P, Lux F, Balosso J, Tillement O, Sancey L, Le Duc G. MRI-guided clinical 6-MV radiosensitization of glioma using a unique gadolinium-based nanoparticles injection. Nanomedicine (Lond). 2016; 11(18): 2405-17.
5. Bolla M, Verry C, Iriart C (2017) “Combination of Androgen deprivation therapy and Radiation Therapy for Locally Advanced and Localized Prostate cancer”. Second Edition In M.Bolla & H.Van Poppel (Eds), Management of Prostate Cancer (pp.217-230). Switzerland: Springer.

5 Relevant projects

1. Investigator coordinator of the clinical trial NANO-RAD (Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles) NCT02820454.
2. Investigator coordinator of the clinical trial NANO-RAD 2: Gadolinium nanoparticles, Phase II multicenter study, NCT03818386.
3. Principal investigator of the clinical trial NCT 02271659, Medical and Economic Evaluation of an External Beam Radiotherapy Combined With a Brachytherapy Boost Compared With an Exclusive External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
4. Principal investigator of the clinical trial NCT 02361515: Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid (RPAH2).
5. Principal investigator of the clinical trial NCT 02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (PEGASUS).